The strong agreement between both in vitro and in silico studies highlights the phenylpropanoid sucrose esters 30–34 as promising candidates for use in future anti-cholinesterase therapeutics against Alzheimer’s disease. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.